WASHINGTON -- Induction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy for patients with moderately to severely active Crohn's disease, topping both ...

In these videos, Sushila Dulal, MD, associate professor of medicine at the University Chicago of Medicine, discusses the latest treatments, state of the pipeline and unmet needs for patients with ...

3 “The results from the Phase 3 studies demonstrate guselkumab has the potential to become the only IL-23 inhibitor to offer both SC and IV induction options for Crohn's disease”, said Mark ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease ... Johnson's Tremfya (guselkumab), and ...

The clearance shores up the competitive position for Omvoh (mirikizumab) in the increasingly competitive inflammatory bowel disease ... (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In ...

MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

3 "The results from the Phase 3 studies demonstrate guselkumab has the potential to become the only IL-23 inhibitor to offer both SC and IV induction options for Crohn's disease”, said Mark Graham, ...

3 “The results from the Phase 3 studies demonstrate guselkumab has the potential to become the only IL-23 inhibitor to offer both SC and IV induction options for Crohn’s disease”, said Mark Graham, ...